SCHEMBL3010296

SCHEMBL3010296

CC1=C(C(=O)N2CCC(c3ccc(C(N)=O)cc3)CC2)C(c2cccc3ccccc23)C2=C(CCCC2=O)N1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.54
KDM4E B2RXH2 10/20 0.54
HPGD P15428 7/20 0.54
HSD17B10 Q99714 6/20 0.54
GAA P10253 5/20 0.48
SMN1; SMN2 Q16637 3/20 0.46
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.42
LMNA P02545 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GLA P06280 1/20 0.41
MAPT P10636 1/20 0.41
FFAR3 O14843 2/20 0.41
CASP1 P29466 2/20 0.40
CASP7 P55210 2/20 0.40
BCHE P06276 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2991081 0.94 ALDH1A1 (0.54) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL3005526 0.93 ALDH1A1 (0.58) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL3119397 0.91 KDM4E (0.52) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL2997411 0.88 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL3005310 0.85 ALDH1A1 (0.64) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL3004470 0.81 ALDH1A1 (0.57) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL2996152 0.80 ALDH1A1 (0.56) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL3004836 0.80 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL3004395 0.78 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL3007058 0.75 KDM4E (0.74) ALDH1A1KDM4EHPGDHSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9045428-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2015-06-02 US disclosed
US-8716319-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2014-05-06 US disclosed
US-20130324525-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-12-05 US disclosed
US-20100197684-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD PALO ALTO, INC. (US) 2010-08-05 US disclosed
US-20090181986-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS, INC. 2009-07-16 US disclosed
US-20090012103-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. 2009-01-08 US disclosed
WO-2009006580-A1 OPTIONALLY CONDENSED DIHYDROPYRIDINE, DIHYDROPYRIMIDINE AND DIHYDROPYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS CV THERAPEUTICS, INC. (US) 2009-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197684-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885KDM4E 1088/4885HPGD 280/4885
US-20130324525-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885KDM4E 1088/4885HPGD 280/4885
US-20090181986-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885KDM4E 1088/4885HPGD 280/4885
US-20090012103-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885KDM4E 1088/4885HPGD 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.